Intranasal Administration of Interleukin-1 Receptor Antagonist in a Transient Focal Cerebral Ischemia Rat Model |
Lee, Jae Hoon
(Department of Anesthesiology and Pain Medicine, Severance Hospital)
Kam, Eun Hee (Anesthesia and Pain Research Institute, Yonsei University College of Medicine) Kim, Jeong Min (Department of Anesthesiology and Pain Medicine, Severance Hospital) Kim, So Yeon (Department of Anesthesiology and Pain Medicine, Severance Hospital) Kim, Eun Jeong (Department of Anesthesiology and Pain Medicine, Severance Hospital) Cheon, So Yeong (Anesthesia and Pain Research Institute, Yonsei University College of Medicine) Koo, Bon-Nyeo (Department of Anesthesiology and Pain Medicine, Severance Hospital) |
1 | Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P. and Thompson, R. C. (1990) Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343, 336-340. DOI |
2 | Allan, S. M., Tyrrell, P. J. and Rothwell, N. J. (2005) Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 5, 629-640. DOI |
3 | Amantea, D., Nappi, G., Bernardi, G., Bagetta, G. and Corasaniti, M. T. (2009) Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 276, 13-26. DOI |
4 | Hunter, A. J., Hatcher, J., Virley, D., Nelson, P., Irving, E., Hadingham, S. J. and Parsons, A. A. (2000) Functional assessments in mice and rats after focal stroke. Neuropharmacology 39, 806-816. DOI |
5 | Iadecola, C. and Anrather, J. (2011) The immunology of stroke: from mechanisms to translation. Nat. Med. 17, 796-808. DOI |
6 | Kim, D. C., Reitz, B., Carmichael, D. F. and Bloedow, D. C. (1995) Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. J. Pharm. Sci. 84, 575-580. DOI |
7 | Lambertsen, K. L., Biber, K. and Finsen, B. (2012) Inflammatory cytokines in experimental and human stroke. J. Cereb. Blood Flow Metab. 32, 1677-1698. DOI |
8 | Loddick, S. A. and Rothwell, N. J. (1996) Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J. Cereb. Blood Flow Metab. 16, 932-940. DOI |
9 | Malerba, F., Paoletti, F., Capsoni, S. and Cattaneo, A. (2011) Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin. Drug Deliv. 8, 1277-1296. DOI |
10 | Martin, D., Chinookoswong, N. and Miller, G. (1994) The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp. Neurol. 130, 362-367. DOI |
11 | Mulcahy, N. J., Ross, J., Rothwell, N. J. and Loddick, S. A. (2003) Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br. J. Pharmacol. 140, 471-476. DOI |
12 | Emsley, H. C., Smith, C. J., Georgiou, R. F., Vail, A., Hopkins, S. J., Rothwell, N. J. and Tyrrell, P. J. (2005) A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatr. 76, 1366-1372. DOI |
13 | Banwell, V., Sena, E. S. and Macleod, M. R. (2009) Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J. Stroke Cerebrovasc. Dis. 18, 269-276. DOI |
14 | Belayev, L., Alonso, O. F., Busto, R., Zhao, W. and Ginsberg, M. D. (1996) Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 27, 1616-1622. DOI |
15 | Chalela, J. A., Merino, J. G. and Warach, S. (2004) Update on stroke. Curr. Opin. Neurol. 17, 447-451. DOI |
16 | Clark, S. R., McMahon, C. J., Gueorguieva, I., Rowland, M., Scarth, S., Georgiou, R., Tyrrell, P. J., Hopkins, S. J. and Rothwell, N. J. (2008) Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J. Cereb. Blood Flow Metab. 28, 387-394. DOI |
17 | Dhuria, S. V., Hanson, L. R. and Frey, W. H., 2nd (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99, 1654-1673. DOI |
18 | Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I. and Lo, E. H. (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40, 2244-2250. DOI |
19 | Fletcher, L., Kohli, S., Sprague, S. M., Scranton, R. A., Lipton, S. A., Parra, A., Jimenez, D. F. and Digicaylioglu, M. (2009) Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J. Neurosurg. 111, 164-170. DOI |
20 | Pradillo, J. M., Denes, A., Greenhalgh, A. D., Boutin, H., Drake, C., McColl, B. W., Barton, E., Proctor, S. D., Russell, J. C., Rothwell, N. J. and Allan, S. M. (2012) Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J. Cereb. Blood Flow Metab. 32, 1810-1819. DOI |
21 | Relton, J. K., Martin, D., Thompson, R. C. and Russell, D. A. (1996) Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp. Neurol. 138, 206-213. DOI |
22 | Simi, A., Tsakiri, N., Wang, P. and Rothwell, N. J. (2007) Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans. 35, 1122-1126. DOI |
23 | Sun, B. L., He, M. Q., Han, X. Y., Sun, J. Y., Yang, M. F., Yuan, H., Fan, C. D., Zhang, S., Mao, L. L., Li, D. W., Zhang, Z. Y., Zheng, C. B., Yang, X. Y., Li, Y. V., Stetler, R. A., Chen, J. and Zhang, F. (2016) Intranasal delivery of granulocyte colony-stimulating factor enhances its neuroprotective effects against ischemic brain injury in rats. Mol. Neurobiol. 53, 320-330. DOI |
24 | Xia, Y., Song, S., Min, Y., Zhong, Y., Sheng, Y., Li, R. and Liu, Q. (2014) The effects of anakinra on focal cerebral ischemic injury in rats. CNS Neurosci. Ther. 20, 879-881. DOI |
25 | Xing, B., Chen, H., Zhang, M., Zhao, D., Jiang, R., Liu, X. and Zhang, S. (2008) Ischemic postconditioning inhibits apoptosis after focal cerebral ischemia/reperfusion injury in the rat. Stroke 39, 2362-2369. DOI |
26 | Garcia, J. H., Wagner, S., Liu, K. F. and Hu, X. J. (1995b) Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 26, 627-634. DOI |
27 | Illum, L. (2004) Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56, 3-17. DOI |
28 | Furrer, E., Hulmann, V. and Urech, D. M. (2009) Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. J. Neuroimmunol. 215, 65-72. DOI |
29 | Galea, J. and Brough, D. (2013) The role of inflammation and interleukin-1 in acute cerebrovascular disease. J. Inflamm. Res. 6, 121-128. |
30 | Garcia, J. H., Liu, K. F. and Relton, J. K. (1995a) Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am. J. Pathol. 147, 1477-1486. |
31 | Grassin Delyle, S., Buenestado, A., Naline, E., Faisy, C., BlouquitLaye, S., Couderc, L., Le Guen, M., Fischler, M. and Devillier, P. (2012) Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol. Ther. 134, 366-379. DOI |
32 | Greenhalgh, A. D., Galea, J., Denes, A., Tyrrell, P. J. and Rothwell, N. J. (2010) Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br. J. Pharmacol. 160, 153-159. DOI |
33 | Gutierrez, E. G., Banks, W. A. and Kastin, A. J. (1994) Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J. Neuroimmunol. 55, 153-160. DOI |
34 | Gueorguieva, I., Clark, S. R., McMahon, C. J., Scarth, S., Rothwell, N. J., Tyrrell, P. J., Hopkins, S. J. and Rowland, M. (2008) Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br. J. Clin. Pharmacol. 65, 317-325. DOI |